Tuttle KR, et al.. Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 2014; 37:2864–2883.

• PubMed
Tuttle KR, . Diabetic kidney disease: a report from an ADA Consensus Conference. Diabetes Care 2014; 37:2864–2883.)| false
• Search Google Scholar
• Export Citation

Centers for Disease Control and Prevention. National Diabetes Statistics Report: estimates of diabetes and its burden in the United States, 2014. Atlanta, GA, U.S. Department of Health and Human Services, 2014.

• PubMed
Centers for Disease Control and Prevention. National Diabetes Statistics Report: estimates of diabetes and its burden in the United States, 2014. Atlanta, GA, U.S. Department of Health and Human Services, 2014.)| false
• Search Google Scholar
• Export Citation

DeBoer IH, et al.. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011; 305:2532–2539.

• PubMed
DeBoer IH, . Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011; 305:2532–2539.)| false
• Search Google Scholar
• Export Citation

Moen MF, et al.. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:1121–1127.

• PubMed
Moen MF, . Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009; 4:1121–1127.)| false
• Search Google Scholar
• Export Citation

DeBoer IH, et al.. Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365:2366–2376.

• PubMed
DeBoer IH, . Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 2011; 365:2366–2376.)| false
• Search Google Scholar
• Export Citation

Perkovic V, et al.. Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83:517–524.

• PubMed
Perkovic V, . Intensive glucose control improves kidney outcomes in patients with type 2 diabetes. Kidney Int 2013; 83:517–524.)| false
• Search Google Scholar
• Export Citation

Kirkman MS, et al.. Diabetes in older adults. Diabetes Care 2012; 35:2650–2664.

• PubMed
Kirkman MS, . Diabetes in older adults. Diabetes Care 2012; 35:2650–2664.)| false
• Search Google Scholar
• Export Citation

Sinclair A, et al.. Diabetes in older people: new insights and remaining challenges. Lancet Diabetes Endocrinol 2015; 3:275–285.

• PubMed
Sinclair A, . Diabetes in older people: new insights and remaining challenges. Lancet Diabetes Endocrinol 2015; 3:275–285.)| false
• Search Google Scholar
• Export Citation

Zoungas S, et al.. Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363:1410–1418.

• PubMed
Zoungas S, . Severe hypoglycemia and risks of vascular events and death. N Engl J Med 2010; 363:1410–1418.)| false
• Search Google Scholar
• Export Citation

Khunti K, et al.. Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 2015; 38:316–322.

• PubMed
Khunti K, . Hypoglycemia and risk of cardiovascular disease and all-cause mortality in insulin-treated people with type 1 and type 2 diabetes: a cohort study. Diabetes Care 2015; 38:316–322.)| false
• Search Google Scholar
• Export Citation

Inzucchi SE, et al.. Management of hyperglycemia in type 2 diabetes 2015: a patient centered approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38:140–149.

• PubMed
Inzucchi SE, . Management of hyperglycemia in type 2 diabetes 2015: a patient centered approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015; 38:140–149.)| false
• Search Google Scholar
• Export Citation

American Diabetes Association. Older adults. Diabetes Care 2015; 38(Suppl 1):S67–S69.

• PubMed
American Diabetes Association. Older adults. Diabetes Care 2015; 38(Suppl 1):S67–S69.)| false
• Search Google Scholar
• Export Citation

Shurraw S, et al.. Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011; 171:1920–1927.

• PubMed
Shurraw S, . Association between glycemic control and adverse outcomes in people with diabetes mellitus and chronic kidney disease: a population-based cohort study. Arch Intern Med 2011; 171:1920–1927.)| false
• Search Google Scholar
• Export Citation

Rabkin R, et al.. The renal metabolism of insulin. Diabetologia 1984; 27:351–357.

• PubMed
Rabkin R, . The renal metabolism of insulin. Diabetologia 1984; 27:351–357.)| false
• Search Google Scholar
• Export Citation

Baldwin D, et al.. A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care 2012; 35:1970–1974.

• PubMed
Baldwin D, . A randomized trial of two weight-based doses of insulin glargine and glulisine in hospitalized subjects with type 2 diabetes and renal insufficiency. Diabetes Care 2012; 35:1970–1974.)| false
• Search Google Scholar
• Export Citation

Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. JAMA 2014; 311:2315–2325.

• PubMed
Wallia A, Molitch ME. Insulin therapy for type 2 diabetes mellitus. JAMA 2014; 311:2315–2325.)| false
• Search Google Scholar
• Export Citation

Inzucchi SE, et al.. Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014; 312:2668–2675.

• PubMed
Inzucchi SE, . Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 2014; 312:2668–2675.)| false
• Search Google Scholar
• Export Citation

Holstein A, Beil W. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Expert Opin Drug Metab Toxicol 2009; 5:225–241.

• PubMed
Holstein A, Beil W. Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Expert Opin Drug Metab Toxicol 2009; 5:225–241.)| false
• Search Google Scholar
• Export Citation

Holstein A, et al.. Hormonal counterregulation and consecutive glimepiride serum concentrations during severe hypoglycaemia associated with glimepiride therapy. Eur J Clin Pharmacol 2003; 59:747–754.

• PubMed
Holstein A, . Hormonal counterregulation and consecutive glimepiride serum concentrations during severe hypoglycaemia associated with glimepiride therapy. Eur J Clin Pharmacol 2003; 59:747–754.)| false
• Search Google Scholar
• Export Citation

Balant L, et al.. Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia 1973; Sep:331–338.

• PubMed
Balant L, . Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia 1973; Sep:331–338.)| false
• Search Google Scholar
• Export Citation

Arjona Ferreira JC, et al.. Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 2013; 36:1067–1073.

• PubMed
Arjona Ferreira JC, . Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency. Diabetes Care 2013; 36:1067–1073.)| false
• Search Google Scholar
• Export Citation

Inoue T, et al.. Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 2003; 60:90–95.

• PubMed
Inoue T, . Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 2003; 60:90–95.)| false
• Search Google Scholar
• Export Citation

Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003; 26:886–891.

• PubMed
Hasslacher C. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 2003; 26:886–891.)| false
• Search Google Scholar
• Export Citation

Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 2014; 68:115–123.

• PubMed
Zhu ZN, Jiang YF, Ding T. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. Bone 2014; 68:115–123.)| false
• Search Google Scholar
• Export Citation

Bergman AJ, et al.. Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007; 30:1862–1864.

• PubMed
Bergman AJ, . Effect of renal insufficiency on the pharmacokinetics of sitagliptin, a dipeptidyl peptidase-4 inhibitor. Diabetes Care 2007; 30:1862–1864.)| false
• Search Google Scholar
• Export Citation

Graefe-Mody U, et al.. Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13:939–946.

• PubMed
Graefe-Mody U, . Effect of renal impairment on the pharmacokinetics of the dipeptidyl peptidase-4 inhibitor linagliptin. Diabetes Obes Metab 2011; 13:939–946.)| false
• Search Google Scholar
• Export Citation

Yamout H, et al.. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol 2014; 40:64–74.

• PubMed
Yamout H, . Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol 2014; 40:64–74.)| false
• Search Google Scholar
• Export Citation

Linnebjerg H, et al.. Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64:317–327.

• PubMed
Linnebjerg H, . Effect of renal impairment on the pharmacokinetics of exenatide. Br J Clin Pharmacol 2007; 64:317–327.)| false
• Search Google Scholar
• Export Citation

Johansen OE, Whitfield R. Exenatide may aggravate moderate diabetic renal impairment: a case report. Br J Clin Pharmacol 2008; 66:568–569.

• PubMed
Johansen OE, Whitfield R. Exenatide may aggravate moderate diabetic renal impairment: a case report. Br J Clin Pharmacol 2008; 66:568–569.)| false
• Search Google Scholar
• Export Citation

Davidson JA, et al.. Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract 2011; 17:345–355.

• PubMed
Davidson JA, . Mild renal impairment and the efficacy and safety of liraglutide. Endocr Pract 2011; 17:345–355.)| false
• Search Google Scholar
• Export Citation